by GlyTherix | Dec 10, 2024 | Glypican-1, GlyTherix, Miltuximab
GlyTherix and Nusano, a physics company transforming the production of radioisotopes, today announced a supply agreement for non-carrier-added lutetium-177 (Lu-177). The agreement also provides GlyTherix access to Nusano’s future actinium-225 (Ac-225) production,...
by GlyTherix | Oct 18, 2024 | GlyTherix
We are pleased to announce GlyTherix is presenting an e-poster titled “Determination of Optimal Imaging Dose of [89Zr]Zr-DFO-Miltuximab and Maximum Tolerated Therapeutic Dose of [177Lu]Lu-DOTA-Miltuximab.” This will showcase our groundbreaking research in...
by GlyTherix | Oct 8, 2024 | GlyTherix
Exciting News in Targeted Radiotherapy! GlyTherix Ltd has signed a global clinical supply agreement with Eckert & Ziegler, a leader in isotopes for nuclear medicine. This collaboration will provide GMP-grade Lutetium-177 chloride for GlyTherix’s clinical...
by GlyTherix | Sep 18, 2024 | GlyTherix
GlyTherix is pleased to announce a new global clinical supply agreement with Wisconsin-based SHINE Technologies, a pioneer in next-generation fusion-based technology and North America’s largest producer of non-carrier added lutetium-177 (n.c.a. Lu-177) chloride....
by GlyTherix | Sep 10, 2024 | GlyTherix, Miltuximab
GlyTherix Ltd is pleased to announce the execution of a Master Service Agreement with 3D Imaging LLC (3DI), a Contract Development and Manufacturing Organization (CDMO), for the manufacture of GlyTherix’s targeted radiotherapy antibody products for its US clinical...
by GlyTherix | Aug 29, 2024 | GlyTherix
GlyTherix is thrilled to be invited to speak at the AusBiotech 2024 National Conference. In a session titled “The rise of radiopharmaceuticals: How Australian biotech is at the forefront of this resurgence” GlyTherix CEO, Dr Brad Walsh will be presenting with other...
